Tampa General Hospital’s Post

Fox News highlights our groundbreaking cancer treatments for breast, ovarian, and other types of cancer - from surgery to immunotherapy, we share the latest options for beating this disease. Read the article to learn more about how we're fighting against cancer! #OasisOfHope #OasisOfHopeTurns60 #cancersupport #fightcancertogether #alternativetherapy #healingwithfood #oncology #healing

Majority of patients with pancreatic cancer in the Netherlands do not receive chemotherapy or other tumor-targeted treatment In a concerted effort to improve pancreatic cancer care in the Netherlands, a nationwide randomized trial involving over 5800 patients assessed patient outcomes before and after the implementation of guidelines based on the latest best practices. One of the key findings of this study is that over 60% of patients with pancreatic cancer did not receive any tumor-targeted therapy, a fact that is reflected in the poor 1-year survival rate (24%) which did not improve measurably. The study, published in JAMA Surgery, offers insights into the real-world challenges of treating pancreatic cancer and calls for identifying strategies that can make a meaningful difference in the lives of these patients. Read more on our website: https://lnkd.in/eP-YEtYC Amsterdam UMC - Cancer Center Amsterdam, #CancerResearch #CancerCare #PancreaticCancer

More practice-changing results from the KEYNOTE-522 trial. 🎉 Such great news for patients with triple negative breast cancer (TNBC), the most aggressive subtype of breast cancer. There’s very few treatment options for TBNC, so having one that provides improved outcomes with fewer side effects than chemotherapy is significant. Most remarkable, patients who still had residual tumor at surgery following neoadjuvant treatment received the most benefit in terms of overall survival. #BreastCancer #TNBC #TripleNegativeBreastCancer #Keytruda #ClinicalTrials #ClinicalResearch https://lnkd.in/g58Q3JqW

Advancing Care in Gynecological Oncology: Early-Stage Vulvar Cancer 🔬 🩺 A comprehensive review by Priscila Grecca Pedrão, Yasmin Medeiros Guimarães, Luani Rezende Godoy, Júlio César Possati Resende, Adriane Cristina Bovo, Carlos Eduardo Mattos Cunha Andrade, Adhemar Longatto-Filho, Ricardo Dos Reis offers new insights into the management of early-stage vulvar cancer, a rare but significant gynecological malignancy. Key Points: Vulvar cancer, primarily squamous cell carcinoma, has two main clinicopathological subtypes, each with distinct etiologies and demographic profiles. The increasing incidence in younger women, typically associated with HPV infection, underscores the need for tailored treatment approaches. Standard treatment involves surgery, often complemented by radiotherapy, depending on the disease stage and histopathology. Sentinel lymph node biopsy has emerged as a crucial component of treatment, reducing complications and informing staging with minimal invasiveness. The review highlights the evolution from invasive surgery to conservative approaches, maintaining oncologic safety while reducing morbidity. Recurrence management and the importance of long-term follow-up are emphasized due to varying prognoses associated with local, groin-associated, or distant recurrences. 🌟 This article provides valuable guidance for healthcare professionals in managing vulvar cancer, focusing on reducing treatment morbidity while ensuring patient safety. 📈 Earn 1.0 CME Credit by engaging with this content. https://lnkd.in/dyWDMJTE #GynecologicalOncology #VulvarCancer #MedicalResearch #PatientCare #OncologyAdvances

Fariba Behbod, PharmD, PhD, has received a $930,000 grant from the U.S. Department of Defense to study a new targeted therapy option for people diagnosed with ductal carcinoma in situ (DCIS). Before breast tumors become invasive, they often start as a condition called DCIS. DCIS is found in about one in every five new breast cancer cases. Typically, DCIS patients undergo aggressive treatments like surgery and radiation. However, only about half of untreated patients will actually develop invasive cancer. In this study led by Dr. Behbod, professor in the department of Pathology and Laboratory Medicine, the main goals are to identify which cases of DCIS are likely to become invasive and treat them appropriately. Learn more ➜ https://bit.ly/3OSAqfy. #DCIS #BreastCancer #KUWCC #BreastCancerResearch

Sarcoma is the general term for a broad group of cancers that can form in various locations in the body, including the bones and the soft tissue (also called connective tissue) that connects, supports, and surrounds other body structures. “I tell patients that sarcomas are like snowflakes,” says CU Cancer Center member Breelyn Wilky, MD. "Sarcomas can be anywhere on the body, head to toe. That’s why it's so important for patients to get a complete evaluation and have a customized treatment plan for their exact situation.” Hear more from Wilky and learn about the latest in sarcoma treatments here: https://lnkd.in/g_wB6TA7 #SarcomaAwareness #CancerCare #Oncology #Oncologist

Improved survival after primary tumor resection in distant metastasis medullary thyroid carcinoma: a population-based cohort study with propensity score matching 🔪 #SurgicalOncology #SurgOnc #Oncology #Cancer

Dr. Poonam Patil, Consultant - Medical Oncology, Manipal Hospital Old Airport Road, elaborates on preventive chemotherapy following Kate Middleton's cancer diagnosis. This treatment is applied after surgery to eliminate residual cancer cells that may remain undetected, reducing the risk of cancer recurrence. It involves potent anti-cancer drugs administered orally or intravenously in multiple treatment cycles. Read this article to learn more about preventative chemotherapy as a treatment option. #ManipalHospitalOldAirportRoad #YourManipal #LifesOn #Healthcare #Chemotherapy #Oncology

A groundbreaking discovery in the fight against brain cancer! Scientists have discovered a simple blood test that could transform the way we diagnose this devastating disease, potentially sparing patients from invasive surgeries. Here's what you need to know: 👉 Understanding Brain Cancer: Brain cancer, particularly glioblastoma, is notoriously difficult to treat due to its location and aggressive nature. Traditional diagnosis often requires risky surgical procedures, but this new blood test offers a non-invasive alternative. 👉 How it Works: The blood test detects specific biomarkers associated with brain cancer, providing valuable diagnostic information without the need for surgery. By analyzing a simple blood sample, clinicians can identify tumors earlier and tailor treatment plans more effectively. 👉 Promising Implications: This breakthrough brings hope for reducing the need for invasive procedures and improving patient outcomes. With further research and development, the future of brain cancer diagnosis looks brighter than ever. Read the full article: https://ow.ly/Ba1L50QBVe4

Lung cancer is by far the leading cause of cancer deaths in the U.S. Most patients have non-small cell lung cancer (NSCLC), and between 25% and 50% of them are diagnosed with “oligometastatic” lung cancer, meaning that they have stage IV disease but that their cancer hasn’t metastasized widely. Traditionally, these patients have not been considered candidates for surgical resection (removal of part or all of the affected lung) since their disease was considered too advanced to be helped by surgery. With advances in systemic therapy for patients, this treatment strategy may need to be revised. Now, findings from a new study by researchers at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) indicate that surgery could be considered as a treatment option for these patients. The team, led by Brendon Stiles, M.D., and Jorge Humberto Rodriguez-Quintero, M.D., used data from the National Cancer Database to identify more than 12,000 treated patients with oligometastatic NSCLC tumors that had only spread to a single metastatic site. As expected, most of the patients 97.1%) received chemotherapy or immunotherapy without surgery, while only a small minority (2.9%) underwent surgical resection in addition to receiving chemotherapy or immunotherapy. Comparing survival for the two groups, the researchers found that patients who received both surgery and systemic therapy lived significantly longer: an average survival of 36.8 months vs. 20.8 months for patients with chemotherapy or immunotherapy and no surgery. Although the patients were not randomized, the researchers concluded that surgical resection of the primary tumor may be underutilized for patients with single-site oligometastatic NSCLC and that surgery may improve overall survival for carefully selected patients with this diagnosis. Their paper was published online on February 9 in the Journal of the American College of Surgeons. Dr. Stiles is professor of cardiothoracic & vascular surgery, of oncology, of medicine, and is associate director of surgical oncology at the MECCC. Dr. Rodriguez-Quintero is a surgical resident and thoracic surgery research fellow at Einstein and Montefiore Health System. #MECCC #OligometastaticLungCancer #LungCancerSurgery #LungCancerTreatment #cancer #CancerCare #health #research